Casdin Capital 13F holdings, Q1 2018
Holdings as of March 31, 2018 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 30 US equity positions worth $565.0m in its Q1 2018 13F filing. The largest position was LOXO ONCOLOGY INC at 7.4% of the reported book, followed by FOUNDATION MEDICINE INC and SG7. Against the Q4 2017 filing, it opened 7 new positions, added to 13 and reduced 0 among the top 30 holdings.
What did Casdin Capital own in Q1 2018? Top 30 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2017 |
|---|---|---|---|---|---|---|---|
| 1 | LOXO ONCOLOGY INC | 7.4% | $41.5m | 360,000 | 0% | held | |
| 2 | FOUNDATION MEDICINE INC | 7.2% | $41.0m | 520,000 | 0% | held | |
| 3 | SG7 SAGE THERAPEUTICS INC | 7.1% | $40.3m | 250,000 | 0% | held | |
| 4 | 2655787D BLUEPRINT MEDICINES CORP | 5.6% | $31.9m | 348,000 | 0% | held | |
| 5 | SPARK THERAPEUTICS INC | 5.5% | $30.8m | 463,000 | 53% | added | |
| 6 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 5.3% | $29.8m | 364,776 | 24% | added |
| 7 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 5.3% | $29.8m | 250,000 | 25% | added |
| 8 | GLOBAL BLOOD THERAPEUTICS IN | 5.1% | $29.0m | 600,000 | 17% | added | |
| 9 | MYOKARDIA INC | 4.8% | $27.3m | 560,000 | 0% | held | |
| 10 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 4.7% | $26.6m | 1,400,000 | 0% | held |
| 11 | FATE FATE THERAPEUTICS INC | Healthcare | 4.5% | $25.4m | 2,600,000 | 0% | held |
| 12 | BLUEBIRD BIO INC | 4.4% | $24.8m | 145,000 | 0% | held | |
| 13 | CDXS CODEXIS INC | Healthcare | 3.9% | $22.3m | 2,025,000 | 27% | added |
| 14 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 3.8% | $21.3m | 1,135,000 | 0% | held |
| 15 | GNMK GENMARK DIAGNOSTICS INC | 3.7% | $20.9m | 3,850,000 | 41% | added | |
| 16 | ILMN ILLUMINA INC | Healthcare | 3.0% | $16.9m | 71,500 | 62% | added |
| 17 | EVH EVOLENT HEALTH INC | Healthcare | 2.8% | $15.8m | 1,110,000 | 3% | added |
| 18 | JOUNCE THERAPEUTICS INC | 2.5% | $14.2m | 635,000 | 34% | added | |
| 19 | AUDENTES THERAPEUTICS INC | 2.4% | $13.5m | 450,000 | 12% | added | |
| 20 | ONC BEIGENE LTD | Healthcare | 2.1% | $11.8m | 70,000 | 289% | added |
| 21 | IBB ISHARES TR | 1.8% | $10.1m | 95,000 | – | new | |
| 22 | CLOVIS ONCOLOGY INC | 1.7% | $9.4m | 177,500 | 39% | added | |
| 23 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.1% | $6.2m | 135,000 | – | new |
| 24 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.0% | $5.9m | 207,500 | 17% | added |
| 25 | EDIT EDITAS MEDICINE INC | Healthcare | 0.8% | $4.4m | 133,333 | 0% | held |
| 26 | NEOG NEOGEN CORP | Healthcare | 0.8% | $4.4m | 65,000 | – | new |
| 27 | OSUR ORASURE TECHNOLOGIES INC | Healthcare | 0.7% | $4.1m | 240,000 | – | new |
| 28 | ZLAB ZAI LAB LTD | Healthcare | 0.5% | $2.9m | 135,000 | – | new |
| 29 | ADVERUM BIOTECHNOLOGIES INC | 0.3% | $1.7m | 300,000 | – | new | |
| 30 | HOMOLOGY MEDICINES INC | 0.2% | $1.1m | 60,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.